ライフサイエンスコーパス: tegaserod

1 of serotonergic agents such as alosetron and tegaserod.

2 inued at a low dose, and was supplemented by tegaserod.

3 Gastric emptying was unaltered by tegaserod.

4 The 5-HT4R agonist tegaserod (1 mg/kg), the 5-HT4R antagonist GR113808 (1 m

5 predominant IBS were randomized to 1 week of tegaserod, 2 mg twice daily, or placebo treatment.

6 s at baseline and after drug administration (tegaserod, 59.5 +/- 2.1 hours; placebo, 62.1 +/- 2.1 hou

7 sure of orocecal transit, was accelerated by tegaserod (70.4% +/- 1.3% [mean +/- SEM] vs. placebo, 46

8 Current examples include tegaserod, a 5-HT(4) partial agonist, which has been app

9 hes include alosetron; a 5-HT(3) antagonist, tegaserod, a partial 5-HT(4) agonist, kappa-opioid agoni

10 Tegaserod accelerates orocecal transit, tends to acceler

11 tion potency, loratadine and simvastatin and tegaserod and promethazine were predicted to have a stro

12 ermine the relationship between promotion of tegaserod and the number of office visits for abdominal

13 ts, selective serotonin reuptake inhibitors, tegaserod, and histamine-2 receptor antagonists have ben

14 recommendations for tenapanor, plecanatide, tegaserod, and lubiprostone (moderate certainty), polyet

15 Tegaserod appeared to have promising results but was pro

16 center at 48 hours were also accelerated by tegaserod compared with baseline, but not compared with

17 Rectal tegaserod did not improve colitis in 5-HT4R knockout mic

18 out mice, and intraperitoneally administered tegaserod did not protect wild-type mice from colitis.

19 ed Promotional Services database to estimate tegaserod DTCA and promotion expenditures; the National

20 3 months immediately following the start of tegaserod DTCA, there was a significant increase in phys

21 Current tegaserod exposure compared to nonexposure was associate

22 5-HT(4) receptor agonists such as tegaserod have demonstrated efficacy in the treatment of

23 Daily administration of tegaserod increased motility in inflamed colons of guine

24 Tegaserod increased proliferation of crypt epithelial ce

25 lamed colons of wild-type mice not receiving tegaserod, inhibition of 5-HT4Rs resulted in signs of co

26 Tegaserod initiators and similar persons who did not ini

27 Among 2,762 tegaserod initiators, there were 94 abdominal or pelvic

28 agents: tenapanor, plecanatide, linaclotide, tegaserod, lubiprostone, polyethylene glycol laxatives,

29 5-HT(4)R compounds included cisapride, tegaserod, naronapride, SB204070, and GR113808.

30 rtial 5-hydroxytryptamine (5-HT)(4) agonist, tegaserod, on gastric small bowel and colonic transit in

31 relationship between physician promotion and tegaserod prescribing was significant; every $1 million

32 romotion (although not DTCA) correlated with tegaserod prescription volume.

33 noses of irritable bowel syndrome (IBS); and tegaserod prescriptions.

34 Rectal administration of tegaserod reduced the severity of colitis compared with

35 ropinirole (RR = 3.21); and promethazine and tegaserod (RR = 3.00).

36 Pre-marketing clinical studies of tegaserod suggested an increased risk of abdominal surge

37 zin, naronapride, plecanatide, prucalopride, tegaserod, tenapanor, or velusetrag) in adults with chro

38 e sought to quantify the association between tegaserod use and the occurrence of abdominal or pelvic

39 In this study, tegaserod use was not found to increase the risk of abdo

40 The initial DTCA of tegaserod was associated with a significant, immediate i

41 ors and similar persons who did not initiate tegaserod were followed for up to six months for the occ